Gary Glick, Odyssey Therapeutics founder
Always busy, Gary Glick recruits OrbiMed in a massive $218M Series A for enigmatic data science biotech
Gary Glick is back at it again, founding yet another biotech company. And by the sheer size of its first raise, this may be the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
